- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01619657
Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis (PRESIS)
Randomized, Double-blind, Controlled Pilot Study on Safety of Hypertonic Saline as Preventive Inhalation Therapy in Newborns and Infants With Cystic Fibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cystic fibrosis (CF) remains one of the most common lethal genetic diseases in Europe and North America. Despite a substantial increase in life expectancy over the past decades, many CF patients still die during young adulthood due to chronic progressive CF lung disease that is caused by defective fluid transport by airway epithelia causing dehydration of airway surfaces, which in turn leads to impaired mucociliary clearance, chronic airway mucus obstruction, inflammation and infection. Recent evidence from studies in a mouse model of CF lung disease suggest that preventive improvement of airway surface hydration may be an effective treatment of early and reversible mucus obstruction and inflammation, and thus delay or ameliorate progressive damage in lungs of CF patients. Hypertonic saline (HS) is an osmotic agent that improves airway surface hydration, and inhalation of 6% HS is already an established, safe, and effective maintenance therapy that improves mucociliary clearance and lung function, and reduces pulmonary exacerbations in older children (> 6 years) and adults with chronic CF lung disease and fixed lung damage. However, the effect of HS as a preventive therapy has not been studied, and no other therapies are available for preventive improvement of airway dehydration and mucociliary dysfunction in CF.
This investigator initiated clinical trial is a monocentric, randomized, double-blind, controlled pilot study on safety and efficacy of a preventive and early inhalation with HS in newborns and infants with CF who are diagnosed in the newborn period either by CF newborn screening (CF-NBS) or for another reason (e.g. meconium ileus) and are younger than 4 months of age at the time of enrolment. Participating patients will be randomized to 6% HS or 0.9% isotonic saline (IS) as active comparator. In both groups, patients will inhale their study solution twice daily over 52 weeks. At the beginning, during and at the end of the study, different measurements will be undertaken to determine effects of HS on safety, radiologic and/or functional alterations of the lung, number of exacerbations, time to first detection of a CF pathogen, and health-related quality of life. We expect that the results of this study will provide first evidence on the safety and efficacy of a preventive therapy that improves airway surface hydration and targets a CF basic defect and may thus delay and/or ameliorate chronic damage of the lungs of patients with CF.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Gießen, Germany, 35392
- University Hospital Giessen and Marburg GmbH
-
Hannover, Germany, 30625
- Medizinische Hochschule Hannover
-
Lübeck, Germany, 23538
- University Children's Hospital Schleswig-Holstein
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69120
- University Children's Hospital Heidelberg, Cystic Fibrosis Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Confirmed diagnosis of CF established in neonatal period either via CF newborn screening (NBS) or because of symptoms typical for CF (e.g. meconium ileus), positive family history or positive prenatal screening and fulfilling at least one of the following three criteria:
- sweat chloride ≥ 60mEq/L
- two CF causing mutations of CFTR gen
- alterations of transepithelial potential difference of nasal or rectal epithelia typical for CF.
- Age at enrolment is 0 to 4 months.
- Patient's and parent's ability to comply with medication use, study visits, and study procedures is judged by the investigator (therefore parents have to understand the character of the study and individual consequences).
- Participation in this study is voluntary. Only patients, whose parents or legal guardians gave written consent, are included.
Exclusion Criteria:
- Born < 30 weeks gestation.
- Prolonged mechanical ventilation in the first 3 months of life.
- A significant medical disease or condition other than CF likely to interfere with the child's ability to complete the entire protocol.
- Previous major surgery except for meconium ileus.
- Other major organ dysfunction, excluding pancreatic or hepatic dysfunction or another condition due to cystic fibrosis.
- Physical findings that would compromise the safety of the subject or the quality of the study data as determined by investigator.
- History of adverse reaction to sedation.
- Known hypersensitivity to study treatment.
- Participation in other interventional studies at the same time.
Criteria, which lead to a displacement of the procedures in sedation until the child has recovered:
- Clinically significant upper airway obstruction as determined by investigator (e.g. severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnoea).
- Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset in 2 weeks preceding visit.
- Oxygen saturation <95% before initial pulmonary function test or initial MRI.
- Severe gastroesophageal reflux, defined as persistent frequent emesis despite anti-reflux therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hypertonic Saline
Inhalation with 6% Hypertonic Saline twice daily over 1 year
|
Administered via inhalation twice daily for 52 weeks.
The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Other Names:
|
Active Comparator: Isotonic Saline
Inhalation with 0.9% Isotonic Saline twice daily over 1 year
|
Administered via inhalation twice daily for 52 weeks.
The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients in both treatment groups with adverse events (AEs) and serious adverse events (SAEs)
Time Frame: during the 52 week treatment period
|
Safety of inhalation with HS and IS in newborns and infants with CF assessed by proportion of adverse events (AEs) and serious adverse events (SAEs)
|
during the 52 week treatment period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of protocol-defined pulmonary exacerbations
Time Frame: during the 52 week treatment period
|
Rate of protocol-defined pulmonary exacerbations requiring treatment with oral, inhaled or intravenous antibiotics between subjects randomized to HS and IS
|
during the 52 week treatment period
|
Time to first pulmonary exacerbation in both treatment groups
Time Frame: during the 52 week treatment period
|
during the 52 week treatment period
|
|
Proportion of children with morphological and/or functional changes due to CF lung disease at baseline and after 1 year of inhalation
Time Frame: during the 52 week treatment period
|
Proportion of children with morphological and/or functional changes due to CF lung disease at baseline and after 1 year of inhalation according to magnetic resonance imaging (MRI) chest score and chest x-ray (CXR) Chrispin-Norman score in both groups (HS vs. IS)
|
during the 52 week treatment period
|
Extent and severity of bronchial dilatation
Time Frame: during the 52 week treatment period
|
Extent and severity of bronchial dilatation after MRI and CXR scores at baseline and after 1 year of inhalation in both groups
|
during the 52 week treatment period
|
Proportion of children with impairments in lung function
Time Frame: during the 52 week treatment period
|
Proportion of children with impairments in lung function determined via multiple breath washout at baseline, after 3, 6, 9, and 12 months of inhalation in both groups
|
during the 52 week treatment period
|
Severity of impairment in lung function test
Time Frame: during the 52 week treatment period
|
Severity of impairment in lung function test at baseline, after 3, 6, 9, and 12 months of inhalation in both groups
|
during the 52 week treatment period
|
Health-related quality of life
Time Frame: during the 52 week treatment period
|
Health-related quality of life as assessed by scores from Cystic Fibrosis Questionnaire - Revised Parent Report (CFQ-R, German version), administered quarterly
|
during the 52 week treatment period
|
Change in anthropometric and basic respiratory parameters
Time Frame: during the 52 week treatment period
|
Change in weight, height, body mass-index, weight-for-height, resting respiratory rate, and room air oxygen saturation
|
during the 52 week treatment period
|
Proportion of patients with new isolation of CF pathogen
Time Frame: during the 52 week treatment period
|
Among participants from whom Pseudomonas aeruginosa or other CF pathogens were not isolated from respiratory cultures prior to enrolment, the proportion from whom these organisms are isolated from clinically collected respiratory cultures
|
during the 52 week treatment period
|
Time to first isolation of a CF pathogen
Time Frame: during the 52 week treatment period
|
Time to acquisition of a CF pathogen is going to be compared between both treatment groups
|
during the 52 week treatment period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marcus A Mall, MD, University Hospital Heidelberg
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UKH-PIHSNC-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis Lung Disease
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Heidelberg UniversityGerman Center for Lung ResearchRecruitingCystic Fibrosis Lung DiseaseGermany
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
Indiana UniversityCompleted
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationNot yet recruitingCystic Fibrosis in ChildrenUnited States
-
University of ManitobaUnknownCystic Fibrosis | Cystic Fibrosis Liver Disease | Pancreatic Insufficiency Due to Cystic Fibrosis of PancreasCanada
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
Synspira, Inc.TerminatedLung Diseases | Cystic Fibrosis | Pulmonary Disease | Antibiotic Resistant Infection | Respiratory Tract Disease | Cystic Fibrosis Pulmonary Exacerbation | Lung Inflammation | Burkholderia Infections | Lung Infection | Multi-antibiotic Resistance | Pulmonary Inflammation | Lung Infection Pseudomonal | Cystic Fibrosis... and other conditionsUnited Kingdom
Clinical Trials on 6% Hypertonic Saline (HS), 4mL
-
Nicole HamblettUniversity of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...Completed
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic FibrosisUnited States
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Neurological... and other collaboratorsTerminated
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaboratorsTerminatedBrain Injuries, TraumaticUnited States, Canada
-
The AlfredCompleted
-
Vrije Universiteit BrusselCompleted
-
Nicole HamblettUniversity of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...Completed
-
University of Washington, the Collaborative Health...Cystic Fibrosis FoundationCompleted
-
CF Therapeutics Development Network Coordinating...National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationCompleted
-
Ahmed Mohamed ELbadawyUnknown